Arun Kumar

TL;DR: The Coalition for Epidemic Preparedness Innovations has developed and is continuously maintaining an overview of the global landscape of COVID-19 vaccine development activity, which includes vaccine development programmes reported through the WHO's authoritative and continually updated list, along with other projects identified from publicly available and proprietary sources.

TL;DR: Issues like awareness generation for risk reduction, frequency of monitoring for selected parameters, standards for monitoring chronic complications in patients with diabetes, and current recommended targets of various parameters, amongst others are presented along with extensions to the vaccinations recommended for diabetic patients.

TL;DR: The development of a novel or improved universal influenza vaccines may be greatly facilitated by new technologies including virus-like particles, T-cell-inducing peptides and recombinant proteins, synthetic viruses, broadly neutralizing antibodies, and nucleic acid-based vaccines.

TL;DR: In this article, the authors summarized novel and traditional approaches for COVID-19 vaccine development including inactivated, attenuated, nucleic acid, vector and protein based, and showed comparative immunogenicity profiles of various vaccines in clinical phases.

TL;DR: Aberrations in the MET receptor tyrosine kinase pathway occur in various human malignancies (via MET amplification, mutation, or overexpression) driving cell proliferation, surviv...